BIOLOGICAL MATERIALS SEPARATION BY CONDUCTIVE MEMBRANES

Information

  • Research Project
  • 3498516
  • ApplicationId
    3498516
  • Core Project Number
    R43GM044468
  • Full Project Number
    1R43GM044468-01
  • Serial Number
    44468
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/1990 - 35 years ago
  • Project End Date
    8/31/1990 - 34 years ago
  • Program Officer Name
  • Budget Start Date
    3/1/1990 - 35 years ago
  • Budget End Date
    8/31/1990 - 34 years ago
  • Fiscal Year
    1990
  • Support Year
    1
  • Suffix
  • Award Notice Date
    2/27/1990 - 35 years ago
Organizations

BIOLOGICAL MATERIALS SEPARATION BY CONDUCTIVE MEMBRANES

DESCRIPTION: (Adapted from the applicant's abstract) Membrane technology for bioseparation has evolved rapidly over the last few years. The development of new polymeric materials and highly asymmetric membranes are two of the major reasons for this evolution. Despite these advances, however, the use of membrane-based processes for bioseparations is still limited by both membrane fouling and gel formation due to protein adsorption. These problems severely limit the efficiency of membrane filtration processes for concentrating products, and virtually disallow the use of membranes for more sophisticated separations such as size selective fraction and biospecific sorption. Recent reports on the investigation of formulating conductive membranes for the preparation of an electric potential barrier to control permeation of the charged species have broadened potential separation processes. In this program, Advanced Surface Technology (AST) will describe innovative new technological approaches for enhancing the purification of biological materials. The applicants will compare the operating characteristics of conductive, electrically charged membranes against standard, non-conductive membranes to determine changes in apparent pore size, retention characteristics and throughput rates. Additional studies of the effects of conductive membrane separation on monoclonal antibodies as well as cell viability for both mammalian and non-mammalian cells, will be initiated.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    AST PRODUCTS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BILLERICA
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01821
  • Organization District
    UNITED STATES